DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report sent to investors on Sunday. The brokerage issued a hold rating on the stock.

Separately, JMP Securities reiterated a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Stock Performance

DBV Technologies stock opened at $6.20 on Friday. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $8.32. The company has a market capitalization of $127.53 million, a price-to-earnings ratio of -1.38 and a beta of 0.71. The stock has a fifty day moving average of $4.45 and a two-hundred day moving average of $3.85.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.